Skip to main content
    H

    Heron Therapeuti (HRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.28
    -0.00 (-0.74%)

    Market Cap: $59.08M

    Last updated: Nov 17, 2026 at 4:41 PM ET

    Heron Therapeuti (HRTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Heron Therapeuti (HRTX) has a market cap of $59.08M and an enterprise value of $173.50M. Its share count is up 12.08% from a year earlier. Its net debt of $114.42M equals 193.66% of its market cap.

    Total Valuation

    Enterprise value is 193.66% above the market cap, as debt exceeds cash.

    Market Cap$59.08M
    Enterprise Value$173.50M
    Latest price (Nov 17, 2026)$0.28

    Key Dates

    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.31% in the quarter ended Sep 30, 2026 and grew 11.77% a year over 2 years.

    Shares Outstanding190.92M
    Shares Change (YoY)+12.08%
    Shares Change (QoQ)+0.31%
    Share Count Growth (2Y CAGR)+11.77%

    Valuation Ratios

    Sales and book value multiples are 0.4x and 13.9x. Its year-end P/S ranged from 1.4x to 402.3x from 2016 to 2025.

    P/S Ratio0.4x
    Forward P/S0.4x
    P/B Ratio13.9x

    Valuation history and multiples

    Price Statistics

    The stock is down 74.35% over 52 weeks and trades 15.15% below its 50-day average.

    Beta (1Y)2.05
    52-Week Change-74.35%
    1-Month Change-21.81%
    3-Month Change-10.38%
    6-Month Change-66.73%
    5-Year Change-97.48%
    10-Year Change-98.13%
    Total Return (1Y)-74.35%
    Total Return (3Y CAGR)-36.26%
    Total Return (5Y CAGR)-51.56%
    Max Drawdown (1Y)-81.88%
    Max Drawdown (3Y)-93.01%
    Sharpe Ratio (1Y)-1.30
    Correlation with SPY (1Y)0.27
    50-Day Average$0.33
    200-Day Average$0.63
    52-Week Range$0.26 to $1.57
    RSI (14 Days)42.0
    Average Volume (20 Days)9.70M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.33x current liabilities, and total debt is 25.63x shareholder equity.

    Current Ratio2.33x
    Quick Ratio1.31x
    Debt / Equity25.63x

    Returns and Efficiency

    Return on invested capital is -8.39% over the last 12 months, against a 5-year average of -0.61%.

    Return on Equity (ROE)-438.57%
    Return on Assets (ROA)-9.36%
    Return on Invested Capital (ROIC)-8.39%
    Return on Capital Employed (ROCE)-9.89%
    ROA (5Y Average)-41.63%
    ROIC (5Y Average)-0.61%
    Asset Turnover0.62x
    Inventory Turnover0.46x
    Receivables Turnover1.68x
    Cash Conversion Cycle916 days

    Scores

    HRTX has an Altman Z-Score of -10.69, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-10.69
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $148.22M over the last 12 months is down 4.44% from the 12 months before.

    Revenue$148.22M
    Revenue Growth (YoY)-4.44%
    Gross Profit$105.93M
    Operating Income-$8.44M
    Pretax Income-$21.56M
    Net Income-$21.56M
    EBIT-$13.90M
    Reported EPS (TTM)-$0.12

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 2.13% of the $230.45M in total assets.

    Cash and Equivalents$11.60M
    Total Debt$126.01M
    Net Debt$114.42M
    Net Debt Per Share$0.60
    Working Capital$119.26M
    Shareholder Equity$4.92M
    Book Value Per Share$0.02
    Total Assets$230.45M
    Total Liabilities$225.53M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $631.00K of capital spending, operating cash flow left -$14.36M of free cash flow.

    Operating Cash Flow-$13.73M
    Capital Expenditures$631.00K
    Free Cash Flow-$14.36M
    FCF Per Share-$0.08
    Depreciation and Amortization$2.35M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -5.69%.

    Gross Margin71.47%
    Operating Margin-5.69%
    Pretax Margin-14.55%
    Net Margin-14.55%
    EBIT Margin-9.38%
    FCF Margin-9.69%
    Gross Margin (5Y Average)58.20%

    Growth

    Revenue grew 12.89% a year over 3 years.

    Revenue Growth (3Y CAGR)+12.89%
    Revenue Growth (5Y CAGR)+11.81%

    Revenue and profit by year

    Dividends and Yields

    HRTX does not pay a dividend.

    Buyback Yield2.35%
    Shareholder Yield2.35%

    Stock Splits

    The last split was a 1-for-20 reverse split on Jan 13, 2014.

    Last Split DateJan 13, 2014
    Split TypeReverse split
    Split Ratio1:20

    Peer Position

    Against 7 similar companies, HRTX has the lowest P/S.

    P/S Ratio0.4x vs 2.4x median
    ROIC-8.39% vs -112.79% median
    Revenue Growth (Trailing 4 Quarters, YoY)-4.44% vs +5.12% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -4.80% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-4.80%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About HRTX

    What is HRTX's market cap?

    Heron Therapeuti has a market cap of $59.08M. Its enterprise value, which adds debt and subtracts cash, is $173.50M.

    How many shares of HRTX are outstanding?

    Heron Therapeuti has 190.92M shares outstanding. The count is up 12.08% from a year earlier.

    Does HRTX pay a dividend?

    No. Heron Therapeuti does not pay a dividend.

    How much debt does HRTX have?

    Heron Therapeuti has $126.01M of total debt and $11.60M of cash and equivalents, a net debt position of $114.42M.